ii SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, or Exchange Act. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends affecting the financial condition of our business. Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward- looking statements are based on information available at the time those statements are made and/or management’s good faith beliefs as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify forward- looking statements by terms such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “anticipate,” “project,” “target,” “design,” “estimate,” “predict,” “potential,” “plan” or the negative of these terms, or similar expressions and comparable terminology intended to identify forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties, including those set forth under the section titled “Risk Factors” and elsewhere in this report. Forward-looking statements include, but are not limited to, statements about: • the success, cost and timing of our development activities, preclinical studies and clinical trials; • the translation of our preclinical results and data and early clinical trial results into future clinical trials in humans; • the number, size and design of clinical trials that regulatory authorities may require to obtain marketing approval, including whether our planned Phase 2 trial in wet AMD will be considered a pivotal trial by the U.S. Food and Drug Administration, or FDA; • the timing or likelihood of regulatory filings and approvals; • our ability to obtain and maintain regulatory approval of our product candidates, and any related restrictions, limitations and/or warnings in the label of any approved product candidate; • our ability to obtain funding for our operations, including funding necessary to develop and commercialize our product candidates; • the rate and degree of market acceptance of our product candidates; • the success of competing products or platform technologies that are or may become available; • our plans and ability to establish sales, marketing and distribution infrastructure to commercialize any product candidates for which we obtain approval; • future agreements with third parties in connection with the commercialization of our product candidates; • the size and growth potential of the markets for our product candidates, if approved for commercial use, and our ability to serve those markets; • existing regulations and regulatory developments in the United States and foreign countries; • the expected potential benefits of strategic collaboration agreements and our ability to attract collaborators with development, regulatory and commercialization expertise; • the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology; • potential claims relating to our intellectual property and third-party intellectual property; • our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; • the pricing and reimbursement of our product candidates, if approved; • our ability to attract and retain key managerial, scientific and medical personnel; • the accuracy of our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; • our financial performance; • our expectations regarding the period during which we qualify as an emerging growth company under the JOBS Act; and • our anticipated use of the proceeds from our initial public offering.